"The world is going to want to find a compromise," said David Kelly, chief market strategist at J.P. Morgan Funds.» Read More
Johnson & Johnson's stock has gained 22 percent on the year and trades at a higher P/E ratio than its competitors. It is not a good buy now, but a great hold, TheStreet.com says.
Robert Zagunis, named one of Moringstar's "Ultimate Stock-Pickers," shares his top three.
A few companies are signaling positive factors for stocks, TheStreet CIO Stephanie Link says.
U.S. stock index futures were lower Wednesday, pressured by some weaker-than-expected earnings and amid worries over global growth.
Earnings season kicks into high gear in the week ahead. Plus, at least 10 Fed speeches. How risk-averse are investors? Oh, this is going to put them to the test. Rest up.
U.S. stock index futures shaved their gains to turn narrowly mixed Wednesday after a report showed private employers added less jobs than expected in March.
At least three of the world's top drugmakers are bidding for Brazil's Ache Laboratorios Farmaceuticos in an auction that may value the group at more than $5 billion, people familiar with the matter said.
Stung by a landmark patent defeat, Western drugmakers will be wary about launching new products in India, but they cannot afford to quit a country with a market potential as large as India's.
Aggregate dividends per share for S&P 500 companies grew nearly 16 percent year-over-year at the end of last year, and the number of companies paying a dividend over the trailing month period hit a new, 13-year high, according to Factset.
The "Fast Money" traders share their final trades of the day and what traders are looking out for on Friday.
Some of the names on the move ahead of the open.
The pharmaceutical and biopharmaceutical sectors have been marching steadily higher. TheStreet.com reports on two stocks with potential to appreciate.
Check out which companies are making headlines after the bell Thursday:
U.S. regulators dealt a major blow to Novo Nordisk's hopes for its new long-acting insulin Tresiba by demanding the Danish drugmaker conduct additional clinical tests to assess potential heart risks.
Earnings beats from Google and IBM boosted Apple stock on Wednesday, as traders bet the one-time darling could regain some of its luster when it reports earnings after the bell.
"I think the market is psychologically prepared to continue without Apple, and if Apple gets involved, it could give it a little bit of an adrenalin shot," one pro said.
A flood of earnings reports, including major technology and industrial companies, could make or break the stock market’s surprise January rally in the week ahead.
After the recent spin-off, should you buy Abbott Labs or the brand new company, AbbVie?
CNBC Contributor Barbara Ryan is taking the pulse of health care stocks at this year's "Woodstock" of health care.
Abbott's portfolio of businesses are aligned with favorable long-term health care and emerging market trends.